Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in the Pharmaceutical Pipeline

ABSTRACT: Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in the Pharmaceutical Pipeline

PROVIDER: PRJNA634154 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11821000_1.fastq.gz	Fastqsanger.gz
	SRR11821000_2.fastq.gz	Fastqsanger.gz
	SRR11821100_1.fastq.gz	Fastqsanger.gz
	SRR11821100_2.fastq.gz	Fastqsanger.gz
	SRR11821200_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 679

Similar Datasets

Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in the Pharmaceutical Pipeline

Project description:Translation of NRF1/NRF2 -mediated liver tissue biomarkers to an in vitro assay using an advanced micropatterned co-culture system (HEPATOPAC®) with primary hepatocytes from male Wistar-Hannover rats or humans

2020-06-22 | GSE150069 | GEO

Pharmaceutical sludge

Project description:Pharmaceutical sludge Metagenome

| PRJNA509337 | ENA

Testing in vitro tools for the prediction of cholestatic liver injury induced by non-pharmaceutical chemicals

Project description:Bile acid accumulation and subsequent liver damage is a frequent adverse effect induced by drugs. Considerable efforts have therefore been focused on the introduction and characterization of tools that allow reliable prediction of this type of drug-induced liver injury. Among those are the cholestatic index and transcriptomic profiling, which are typically assessed in in vitro settings. The present study was set up to test the applicability of both tools to non-pharmaceutical compounds with cholestatic potential, including the industrial compound bis(2-ethylhexyl)phthalate, the cosmetic ingredients triclosan and octynoic acid, the herbicides paraquat and quizalofop-para-ethyl, and the food additives sunset yellow and tartrazine, in a human hepatoma cell culture model of cholestatic liver injury. The cholestatic index method showed cholestatic liability of sunset yellow, tartrazine and triclosan. Of those, tartrazine induced transcriptional changes reminiscent of the transcriptional profile of cholestatic drugs. Furthermore, a number of genes were found to be uniquely modulated by tartrazine, in accordance with the cholestatic drugs atazanavir, cyclosporin A and nefazodone, which may have potential as novel transcriptomic biomarkers of chemical-induced cholestatic liver injury. In conclusion, unambiguous identification of the non-pharmaceutical compounds tested in this study as inducers of cholestasis could not be achieved.

2021-03-18 | GSE169072 | GEO

GNPS - Glutathione adduct_in vitro_human liver microsomes

Project description:GSH adduct formed via in vitro bioactivation in human liver microsomes

2023-11-01 | MSV000093215 | GNPS

Pharmaceutical degrading enrichment cultures

Project description:Pharmaceutical degrading enrichment cultures Raw sequence reads

| PRJNA782474 | ENA

Activated sludge from Pharmaceutical industry

Project description:Activated sludge from Pharmaceutical industry Metagenome

| PRJNA509309 | ENA

Castanet pipeline validation study

Project description:Castanet pipeline validation study

| PRJEB77004 | ENA

Polydopamine nanoparticles as a potential pharmaceutical tool in the treatment of non-alcoholic fatty liver disease

Project description:Non-alcoholic fatty liver disease (NAFLD), or hepatic steatosis, has become one of the most common pathologies among liver-related disorders. The rapid accumulation of fat in this organ, and the consequent increment in oxidative stress levels, have been recognized as one of the main factors involved in the pathological mechanism underlying hepatic steatosis, and progressive non-alcoholic steatohepatitis. Experimental and epidemiological data have shown how antioxidant compounds rich in phenolic groups, such as resveratrol and quercetin, are particular efficient in contrasting the onset of this pathology. In this work, an in vitro model of NAFLD was established based on oleic acid-treated HepG2 cells. Steatotic cells were treated with polydopamine nanoparticles (PDNPs), biocompatible polymeric nanostructures rich in phenolic groups with high antioxidant power. PDNP treatment has shown to be effective in counteracting the hallmarks characterizing hepatic steatosis, and a reduction in the accumulation of lipids has been observed. Further analyses also showed a significant reduction in triglyceride and cholesterol levels, jointly to reduced levels of oxidative stress. Altogether, collected findings suggest PDNPs to be a promising pharmaceutical candidate for the prevention and treatment of hepatic steatosis.

2024-10-02 | PXD046524 | Pride

Auricularia auricula polysaccharides reduce obesity in mice through gut commensal Papillibacter cinnamivorans [liver]

Project description:Auricularia auricula polysaccharides reduce obesity in mice through gut commensal Papillibacter cinnamivorans [liver]

| PRJNA839266 | ENA

Air and dust from pharmaceutical factories

Project description:Air and dust from pharmaceutical factories Metagenome

| PRJNA1004882 | ENA